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Genetic susceptibility accounts for 35% of all colorectal can-
cer (CRC). Ten common low-risk variants contributing to CRC
risk have been identified through genome-wide association
studies (GWASs). In our GWAS, 610 664 genotyped single-
nucleotide polymorphisms (SNPs) passed the quality control
filtering in 371 German familial CRC patients and 1263 con-
trols, and replication studies were conducted in four additional
case–control sets (4915 cases and 5607 controls). Known risk
loci at 8q24.21 and 11q23 were confirmed, and a previously un-
reported association, rs12701937, located between the genes
GLI3 (GLI family zinc finger 3) and INHBA (inhibin, beta A)
[P 5 1.1 3 1023, odds ratio (OR) 1.14, 95% confidence interval
(CI) 1.05–1.23, dominant model in the combined cohort], was
identified. The association was stronger in familial cases com-
pared with unselected cases (P 5 2.0 3 1024, OR 1.36, 95% CI
1.16–1.60, dominant model). Two other unreported SNPs,
rs6038071, 40 kb upstream of CSNK2A1 (casein kinase 2, alpha
1 polypeptide) and an intronic marker inMYO3A (myosin IIIA),
rs11014993, associated with CRC only in the familial CRC cases
(P 5 2.5 3 1023, recessive model, and P 5 2.7 3 1024, domi-
nant model). Three software tools successfully pointed to the
overrepresentation of genes related to the mitogen-activated
protein kinase (MAPK) signalling pathways among the
1340 most strongly associated markers from the GWAS
(allelic P value < 1023). The risk of CRC increased significantly
with an increasing number of risk alleles in seven genes
involved in MAPK signalling events (Ptrend 5 2.2 3 10216,
ORper allele 5 1.34, 95% CI 1.11–1.61).
Introduction
Colorectal cancer (CRC) is the third most common cancer and the
fourth-leading cause of cancer death worldwide, with a lifetime
risk in Western European and North American populations 5%.
The majority of CRC cases (up to 80%) are sporadic (1), indicating
that both genetic and environmental factors contribute to the
disease aetiology, with inherited susceptibility being responsible
for 35% of all CRC (2). However, hereditary high-risk germ
line mutations in the APC gene, the DNA mismatch repair genes,
MUTYH, and more rarely in the SMAD4, BMPR1A and STK11/
LKB1 genes account for 3.6% of all cases, according to a Finish
study (3).
To date, three genome-wide association studies (GWASs) (4–6),
followed by a series of fast-tracked publications (7–9), have been
carried out for CRC, leading to the identification of six susceptibility
loci (8q23.3, 8q24.21, 10p14, 11q23, 15q13.3 and 18q21). A subse-
quent meta-analysis (10) of two of the three GWASs yielded four
novel risk loci (14q22.2, 16q22.1, 19p13.1 and 20p12.3), including
confirmation of these associations in additional large sample sets.
Several follow-up studies have replicated these associations through
genotyping of thousands of individuals (11–19). Despite this enor-
mous effort, these 10 common low-penetrance variants exert only
subtle effects on cancer risk, with odds ratios (ORs) ranging 1.1
to 1.2 (20), whereas the joint population attributable fraction for the
first six risk loci described (without including the meta-analysis) was
52% (21). Thus, most of the estimated inherited susceptibility for
CRC remains unknown.
We performed a GWAS on 384 German familial cases and 1285
ethnically matched healthy controls on the Affymetrix Genome
Wide Human SNP Array 6.0 [906 600 single-nucleotide polymor-
phisms (SNPs)]. Familial cases were selected because they might
be genetically enriched for susceptibility alleles, thus providing
enhanced power to detect an association (22,23). Selected associ-
ated SNPs were included in up to four replication studies. There is
an increasing focus on the idea of a complex interplay of molecules
in a common pathway contributing to disease aetiology (24).
Abbreviations: CI, confidence interval; CRC, colorectal cancer; EGFR, epi-
dermal growth factor receptor; GO, Gene Ontology; GWAS, genome-wide
association study; LD, linkage disequilibrium; MAPK, mitogen-activated pro-
tein kinase; MDR, multifactor-dimensionality reduction; OR, odds ratio; SNP,
single-nucleotide polymorphism.













Accordingly, we performed overrepresentation analyses among
the most strongly associated SNPs from our GWAS (allelic
P value , 103) using three software tools, in order to search
for enrichment of pathways or Gene Ontology (GO) categories.
Materials and methods
Study populations
A total of 384 unrelated familial CRC cases were included in the GWAS, 315
of them were identified from the regional cancer registry of Schleswig-
Holstein (Germany) (25) and another 69 were included from the German
HNPCC Consortium (Table I). Samples from the HNPCC Consortium were
tested to be microsatellite stable (none of the five markers tested showed in-
stability) and thus negative for germ line mutations in MSH2 and MLH1 (26).
All patients had at least one first-degree relative with CRC (71% one relative,
16% two relatives, 7% three or more relatives and 6% with unknown number).
The 1285 healthy controls, free of CRC at the time of recruitment, were
randomly selected from the population-based control pool of the PopGen pro-
ject in Schleswig-Holstein (Germany) (27).
Replication study 1 included 575 additional, independent CRC cases from
the German HNPCC Consortium (26), also tested to be microsatellite stable.
The 760 healthy controls were healthy voluntary blood donors recruited in
Mannheim (Germany) (28). Replication 2 comprised 2173 or 1908 additional,
independent cases identified from the cancer registry of Schleswig-Holstein, as
well as 2552 or 1752 controls (Table II): 322/293 additional controls from the
PopGen project and 2230/1459 randomly selected population-derived controls
from the SHIP (Study of Health In Pomerania) study, free of CRC at the time of
recruitment, and also from Northern Germany (29). Replication 3 included
1373 CRC cases and 1480 controls from the population-based DACHS
(DArmkrebs: CHancen der Verhuetung durch Screening—CRC: chances of
prevention through screening) study in the Rhine-Neckar region in the south-
west of Germany (30). DACHS cases were recruited during first hospitalization
due to cancer treatment or shortly afterwards at their homes, whereas controls
were randomly selected from lists of residents supplied by population regis-
tries. Finally, replication 4 consisted of 794 CRC cases and 815 hospital-based
colonoscopy negative controls from the Czech Republic (31). Controls were
undergoing colonoscopy for various gastrointestinal complaints and in the
frame of preventive examination. Only subjects whose colonoscopy results
were negative for malignancy, colorectal adenomas, benign polyps or idio-
pathic bowel disease were chosen as controls, and this guarantees a very low
risk of CRC for the next 20 years (30). For a further description of all patient
and control groups see Table I.
The study protocols were approved by the ethics committee of all partici-
pating clinical centres. Written informed consent was obtained from all study
participants.
GWAS
DNA was extracted from peripheral venous blood. All samples initially in-
cluded in the GWAS (384 cases, 1285 controls) were genotyped for 906 600
SNPs using the Affymetrix 6.0 array by Affymetrix (Santa Clara, CA) accord-
ing to the Affymetrix’s protocol, together with 14 Affymetrix controls.
Thirteen CRC cases and 22 controls failed genotyping due to standard
quality control of genotype data by Affymetrix (call rate , 86% or preliminary
Birdseed call rate , 95%), leaving a total of 371 cases and 1263 controls that
were included in the association study.
Primary data analysis was performed with the Affymetrix Genotyping Con-
sole software, and the genotype calling was done using the Birdseed 2
algorithm in Affymetrix Power Tool (http://www.affymetrix.com/partners_
programs/programs/developer/tools/powertools.affx). Before analysis, we ex-
cluded markers with one or more of the following criteria: ,90% genotype call
rate (61 152 SNPs), minor allele frequency , 5% in cases or controls (224 200
SNPs) or Hardy–Weinberg equilibrium exact P value , 105 in cases or
controls (78 289 SNPs). Additional 352 SNPs were rejected after visual quality
inspection of the clustering pattern (32) using Affymetrix Genotyping Console
(v3.0.2). Finally, 610 664 SNPs passed all quality control filters, with an
average call rate of 97.5%.
To evaluate the evidence for association between each genotyped SNP and
CRC, we first calculated the association between SNPs and CRC for allelic,
genotype, dominant and recessive models based on logistic regression, using
the whole-genome analysis package PLINK with the ‘model’ option (33), as
we do not know whether variants are probably to add additively, dominantly or
recessively. A total of 523 SNPs showed at least one of the four calculated
P values for association (allelic, genotype, dominant or recessive) , 104 and
reliable clustering. The Manhattan plot, which plots log10 of the allelic
P value of each SNP along chromosomes and physical positions, was created
by the genetic analysis package in CRAN R (http://cran.r-project.org/web
/packages/gap/index.html). The impact of population stratification was evalu-
ated by calculating the genomic control inflation factor lambda (k) using the
‘qqunif()’ function in CRAN R. The genomic control k value of 1.08 indicated
a minimal overall inflation due to population stratification. This value of k is
identical with the recent results comparing Northern and Southern German
populations (34). Given that the impact factor was found to be minimal, all
the statistical results are reported without genomic control correction.
Since Bonferroni correction for multiple testing is agreed to be overly con-
servative in GWASs (35), we followed the Wellcome Trust Case Control Con-
sortium thresholds of P , 1  105 and P , 5  107 as moderate and strong
evidence for association, respectively (36).
Forward SNP selection procedure
Among the 523 SNPs with one of the four calculated P values for
association ,104 and reliable clustering, selection for replication studies
was based not only on the most extreme P values, but also on the following
criteria, in an attempt to select the best candidate markers for CRC (37):
Table I. Details of individual case–controls series used in the genome-wide and the replication studies







Cases Germany (Kiel þ HNPCC
Consortium)
384 68.2 (49–86)a 0.99 64.4 (47–83)a
No data (HNPCC) 46.5 (15–76)b




575 No data 0.98 43.4 (9–82)
Controls Germany (Mannheim) 760 45.9 (26–68) 1 —
Replication 2
Cases Germany (Kiel) 2173 66.9 (17–94) 1.17 63.0 (10–90)
Controls Germany (PopGen) 322 73.6 (50–81) 0.86 —
Germany (SHIP) 2230 60.9 (21–81) 0.92 —
Replication 3
Cases Germany (DACHS) 1373 68.6 (33–95) 1.35 68.1 (33–94)
Controls Germany (DACHS) 1480 68.0 (34–98) 0.94 —
Replication 4
Cases Czech Republic 794 62.3 (27–90) 1.33 61.1 (27–90)
Controls Czech Republic 815 54.4 (28–91) 1.38 —
SHIP, Study of Health In Pomerania; DACHS, Darmkrebs: CHancen der Verhuetung durch Screening (CRC: chances of prevention through screening).
aOnly for the 170 cases from Kiel with full data.
bHNPCC Consortium samples.














(i) Two or more SNPs located within or close to a gene or intergenic but not
further than 150 kb from each other (so-called ‘SNP-clusters’) (37 SNPs);
(ii) SNPs located within known risk loci for CRC, according to previous
GWASs [8q24.21 (5,6), 18q21 (7), 8q23.3 (9), 10p14 (9), 15q13.3 (8), 11q23
(4), the not confirmed 9p24 (6) and the four loci from a meta-analysis
14q22.2, 16q22.1, 19p13.1 and 20p12.3 (10)] (2 SNPs); (iii) SNPs located
in 451 candidate genes for CRC, based on high-throughput mutation analy-
ses in CRC tumours (38,39), their possible relevance for CRC biology (6), or
a transposon-based genetic screen in mice (40) (15 SNPs); (iv) coding SNPs
(5 SNPs) and/or (v) comparison with the results of an unpublished GWAS for
CRC (Jochen Hampe, personal communication) (18 SNPs). This resulted in
selection of 53 SNPs for replication, 51 of them were successfully genotyped
in replication 1 (see supplementary Table 1, available at Carcinogenesis
Online). The 470 SNPs not included in replication studies are listed in
supplementary Table 2, available at Carcinogenesis Online.
Replication studies
All DNAs used in the replication studies were extracted from peripheral ve-
nous blood and subjected to genome-wide amplification using the illustra
GenomiPhi V2 DNA Amplification Kit (GE Healthcare, Freiburg, Germany)
according to manufacturer’s instructions. Genotyping was performed at the
German Cancer Research Center in Heidelberg and at the University of Kiel
(Germany), using 5 ng of genomic amplified DNA in 384-well plate format,
using KASPar assays on demand (50 SNPs) (KBiosciences, Hoddesdon, UK)
or TaqMan (one SNP) (Applied Biosystems, Darmstadt, Germany) technolo-
gies and following the manufacturers’ protocols. Average genotyping call rate
was 98%. Calculation of linkage disequilibrium (LD) and reconstruction of
haplotypes between rs12701937 and rs10441105 at 7p14.1 were performed
using Haploview (41). All joint analyses of replication studies were adjusted
for study centre.
Overrepresentation analysis and gene–gene interactions
Three different tools were used to search for enrichment of pathways or Gene
Ontology (GO) categories among the associated polymorphisms. The recently
published approach ALIGATOR (42) considers the biological pathways as
a unit of analysis, and tests for overrepresentation of categories of genes de-
fined by GO terms on a list of significant SNPs, which are selected according to
an arbitrary threshold of significance in the GWAS. The 610 664 SNPs ana-
lysed and their corresponding allelic P values for association were used as
input, with default settings for calculations (5000 replicate gene lists and 1000
replicate studies). Three different thresholds for allelic P values of SNPs in the
GWAS were tested in order to define a significantly associated SNP set for
the enrichment analysis; 104 (153 SNPs), 103 (1340 SNPs) and 5  103
(5130 SNPs). The highest level of significance for overrepresentation of
GO categories was obtained using, as input list, the 1340 SNPs with allelic
P value , 103, located within 350 different genes (Table IV). For all three
cut-offs, ALIGATOR analysis was restricted to those SNPs from the input list
located within genes, and only GO categories containing two or more genes
were counted.
ConsensusPathDB (43) integrates more than 12 different interaction data-
bases and 1738 pathways and carries out overrepresentation analysis within an
uploaded gene list (pathway-based set enrichment tool). Input list of genes
consisted of the 350 genes with SNPs associated in the GWAS with allelic
P value , 103, also used by ALIGATOR for overrepresentation analysis.






ORhet. (95% CI) ORhom.
(95% CI)
Best model P value OR (95% CI)
rs12701937 (7p14.1) [T]
GWAS 371 1263 0.47 0.39 1.09 (0.83–1.42) 2.22 (1.59–3.11)
Replication 1 575 760 0.48 0.40 1.58 (1.23–2.03) 1.76 (1.28–2.41)
Replication 2a 2173 2552 0.46 0.44 1.12 (0.98–1.28) 1.06 (0.90–1.26)
Replication 3 1373 1480 0.42 0.42 1.00 (0.85–1.19) 1.02 (0.82–1.26)
Replication 4 794 815 0.45 0.46 1.00 (0.77–1.29) 0.88 (0.64–1.21)
All replications 4915 5607 1.12 (1.02–1.22) 1.10 (0.98–1.23) Dominant 1.3  102 1.11 (1.02–1.21)
GWAS þ
replications
5286 6870 1.11 (1.02–1.21) 1.21 (1.09–1.35) Dominant 1.1  103 1.14 (1.05–1.23)
rs6038071 (20p13) [T]
GWAS 371 1263 0.11 0.07 1.66 (1.22–2.24) 4.61 (1.23–17.3)
Replication 1 575 760 0.12 0.09 1.19 (0.90–1.57) 2.54 (1.01–6.42)
Replication 2a 1908 1752 0.09 0.09 0.94 (0.79–1.12) 0.73 (0.33–1.60)
Replication 3 1373 1480 0.09 0.09 0.89 (0.72–1.08) 2.28 (1.03–5.05)
All replications 3856 3992 0.96 (0.85–1.08) 1.50 (0.94–2.39) Recessive 8.4  102 1.50 (0.94–2.40)
GWAS þ
replications
4227 5225 1.05 (0.94–1.17) 1.80 (1.15–2.80) Recessive 9.4  103 1.78 (1.15–2.77)
rs11014993 (10p12.1) [C]
GWAS 371 1263 0.24 0.21 0.86 (0.67–1.10) 3.05 (1.78–5.22)
Replication 1 575 760 0.25 0.20 1.49 (1.18–1.88) 1.18 (0.73–1.91)
Replication 2a 1908 1752 0.21 0.22 0.98 (0.85–1.14) 0.78 (0.56–1.08)
Replication 3 1373 1480 0.20 0.21 0.96 (0.82–1.13) 0.81 (0.56–1.18)
All replications 3856 3992 1.05 (0.95–1.16) 0.85 (0.69–1.06) Recessive 1.0  101 0.84 (0.67–1.03)
GWAS þ
replications
4227 5225 0.99 (0.91–1.08) 1.05 (0.86–1.29) Recessive 7.2  101 1.04 (0.85–1.27)
rs12296076 (11q23 locus) [G]
GWAS 371 1263 0.38 0.30 1.99 (1.51–2.62) 1.49 (0.92–2.40) Dominant 1.8  106 1.90 (1.46–2.49)
Replication 1 575 760 0.33 0.28 1.30 (1.03–1.64) 1.53 (1.04–2.24) Dominant 8.8  103 1.34 (1.08–1.67)
rs10956369 (8q24.21 locus) [T]
GWAS 371 1263 0.48 0.40 1.25 (0.96–1.64) 2.03 (1.46–2.82) Recessive 6.4  105 1.77 (1.33–2.35)
Replication 1 575 760 0.44 0.37 1.35 (1.06–1.72) 1.75 (1.27–2.41) Recessive 7.1  103 1.48 (1.11–1.97)
rs10441105 (7p14.1) [C]
GWAS 371 1263 0.45 0.53 0.55 (0.41–0.72) 0.55 (0.40–0.78) Dominant 2.2  105 0.55 (0.42–0.72)
Replication 1 575 760 0.42 0.48 0.83 (0.64–1.07) 0.61 (0.44–0.83) Recessive 6.1  103 0.68 (0.52–0.90)
Minor allele for each SNP is indicated in square brackets; MAF, minor allele frequency; OR (95% CI) for heterozygous (ORhet.) and homozygous (ORhom.)
genotypes are shown; P value and OR (95% CI) for the best model. All joint analyses were adjusted for study centre.















Background consisted of all genes with SNPs among the 610 664 analysed in
the GWAS.
Finally, ToppGene Suite (44) was applied to rank a list of genes (test set)
based on functional similarity (ToppGene tool) or topological feature in
protein–protein interaction network (ToppNet tool) to a training gene list
(training set). In both cases (ToppGene and ToppNet tool), the test gene list
(test set) consisted of the same 350 genes from associated SNPs of the GWAS,
also used for ALIGATOR and ConsensusPathDB. The training gene list (train-
ing set) consisted of 459 candidate genes for CRC, which included the 451
genes used for selection of SNPs for replication analysis (criterion c, see
Materials and Methods/forward SNP selection procedure) and the eight genes
located in or close to the known risk loci for CRC from previous GWASs
(SMAD7, EIF3H, SCG5, GREM1, FMN1, BMP4, CDH1 and RHPN2) (20).
For each gene in the test gene list, the ToppGene tool derives a similarity score
to the training gene list for 14 different features and combines all similarity
scores into an overall score using statistical meta-analysis.
All three software tools pointed out to an overrepresentation of genes related
to mitogen-activated protein kinase (MAPK) signalling events, with seven
genes directly implicated in the MAPK signalling pathways in CRC (45).
Therefore, the effect of an increasing number of risk alleles (one risk allele
per each of the seven genes) on CRC risk was calculated from the GWAS data
by counting two for a homozygote and one for a heterozygote genotype.
Epistasis between associated polymorphisms of the seven selected MAPK-
related genes was tested using both logistic regression and multifactor-
dimensionality reduction (MDR) methods for interaction. Logistic regression
and MDR are two commonly used methods to estimate interaction between
polymorphisms in association studies for complex diseases (46). Pair-wise
interactions between the seven SNPs from MAPK-related genes were studied
by logistic regression using the option ‘epistasis’ in the package PLINK (33),
which assumes an allelic by allelic epistasis model for the interactions. For
each SNP, all possible pair-wise combinations were tested. MDR is considered
a non-parametric alternative to logistic regression for detecting interaction
between polymorphisms. This model-free, non-parametric data reduction
method classifies multi-locus genotypes into high-risk and low-risk groups (47).
The MDR version 2.0 and the MDRpt version 1.0 module for permutation
testing are open-source and freely available software (http://www.epistasis.
org/). The software estimates the importance of the signals by using both
cross-validation and permutation testing, which generates an empirical P value
for the result. Additionally, a dendrogram shows the type of interaction
between each pair of SNPs (epistasis, independence or redundancy).
Results
Supplementary Figure 1, available at Carcinogenesis Online, de-
scribes the individual steps from GWAS to replication studies and
overrepresentation analysis.
GWAS
Four SNPs reached genome-wide strong evidence for association at
allelic level (P , 5  107) (Figure 1): rs2209907 (P 5 3.4  108),
located 0.8 Mb from TLE4 (transducin-like enhancer of split 4);
rs16823149 (P 5 5.5  108), intronic in the open reading frame
C1orf21; rs4140904 (P 5 1.4  107), located 0.5 Mb from NCAPG
(non-SMC condensing I complex, subunit G) and rs4574118
(P 5 1.8  107), located 250 kb from PLGLA (plasminogen-like
A, non-coding RNA). The polymorphism rs2209907 was selected for
replication because it fulfilled two of the selection criteria used. For
the other three markers, none of the linked SNPs showed association,
and they were considered association artefacts.
No clear SNP peaks were identified in the Manhattan plot at the ge-
nome-wide significance level (P , 5  107), whereas a cluster of three
SNPs at chromosome 3 on the gene FAM19A1 [family with sequence
similarity 19 (chemokine C-C motif-like), member A1] reached moder-
ate evidence for association (P , 1  105) (Figure 1).
Sixteen additional SNPs reached moderate evidence for association
(allelic P , 1  105) (Figure 1). From the 10 CRC risk loci iden-
tified in previous GWASs (20), our study identified rs10956369 (al-
lelic P 5 4.2  105) at locus 8q24.21 and rs12296076 (allelic
P 5 2.4 104) at locus 11q23 among the 523 SNPs with a P value,
104. At chromosome 8q24.21, three additional polymorphisms re-
ported in the previous GWASs were also associated, but at a lower
level (rs10505477, P 5 5.9  104; rs6983267, P 5 7  104 and
rs7014346, P 5 2.5  104). At the other eight risk loci from pre-
vious GWASs, our study did not show association at P , 102 for any
of the reported SNPs or for any marker in LD with them. At the
20p12.3 region, the two previously reported SNPs rs961253 and
rs355527 (10) were not present in our array, and the linked polymor-
phism rs2423154 showed a P value of 2.1  103 for a dominant
model.
Using additional functional and positional criteria as described in
Materials and Methods, we selected 53 SNPs for replication studies
from the SNPs with a P value ,104 (supplementary Tables 1 and 2
are available at Carcinogenesis Online).
Replication 1
From the 53 SNPs selected for replication, 51 were successfully gen-
otyped in 575 familial CRC cases (collected by the German HNPCC
Consortium) and 760 controls (supplementary Table 1 is available at
Carcinogenesis Online). A total of six SNPs showed nominal associ-
ation at allelic level (P , 5  102): the two SNPs located in the
known CRC risk loci, rs10956369 at 8q24.21 (P 5 2.5  104) and
rs12296076 at 11q23 (P 5 5.9  103); one intronic marker in
MYO3A (myosin IIIA), rs11014993 (P 5 7.2  103); rs6038071
(P 5 3.9  102), located 40 kb upstream of CSNK2A1 (casein ki-
nase 2, alpha 1 polypeptide); two SNPs in high LD (Haploview LD
plot: D# 5 1.0, r2 5 0.62 in the 760 controls) located between the
genes GLI3 (GLI family zinc finger 3) and INHBA (inhibin,
beta A), rs12701937 (P 5 1.1  104) and rs10441105 (P 5 2.1 
103). For these last two SNPs, the haplotype T-G, containing the
risk alleles of the two SNPs, was also associated with CRC
(P 5 8.0  104 in the GWAS, P 5 1.0  104 in replication 1).
Additional replications
From the six SNPs associated in replication 1, we selected three for
further replication analysis (Table II): rs12701937 between GLI3 and
INHBA, which is in high LD with rs10441105; rs6038071, close to
CSKN2A1, and rs11014993, the MYO3A intronic polymorphism. The
two SNPs located in the risk loci 8q24.21 (rs10956369) and 11q23
(rs12296076) were not included in the further replications.
For rs12701937, none of the replications 2–4 showed association of
this SNP with CRC. Joint analysis of all replication studies reached
a borderline significance (P 5 1.3  102 for dominant model,
OR 1.11, 95% CI 1.02–1.21) (Table II).
For rs11014993 and the rare rs6038071, neither replications 2–3
nor joint analysis of all of them showed association for any of the two
SNPs with the risk of CRC (Table II). Only for rs6038071, a recessive
inheritance model did show an association (P 5 9.4  103, OR 1.78,
95% CI 1.15–2.77, for the joint analysis of GWAS and the replica-
tions, Table II). However, this result should be taken with caution due
to the low number of samples homozygous for the risk allele (48 cases
and 34 controls).
When considering only familial cases of CRC (all cases from rep-
lication 1, 6% from replication 2 and 13% from replication 3), the
associations were stronger than for all patients together, which were
mostly sporadic cases (Table III). For a total of 880 familial cases and
4790 controls from replications 1–3, the P value for rs12701937 was
2.0  104 and OR 1.36 (95% CI 1.16–1.60) for a dominant model. For
rs6038071, the P value was 2.5  103 for a recessive model (OR 2.49,
95% CI 1.35–4.59), and for rs11014993, it was 2.7  104 for a dom-
inant model (OR 1.32, 95% CI 1.14–1.54).
Overrepresentation analysis and gene–gene interactions
All three software tools used to detect enrichment of particular GO or
pathway categories among associated SNPs from the GWAS pointed
out to an overrepresentation of genes related to MAPK signalling
events. First, the ALIGATOR software identified a significant enrich-
ment of 73 GO categories among the 1340 most significantly associ-
ated SNPs (in 350 genes) from the GWAS with allelic P value , 103
(Table IV). Nine of these enriched categories were related to the
MAPK activities and four of them ranked in the first eight most














significant positions (supplementary Table 3A is available at Carci-
nogenesis Online). Genes with SNPs among the nine MAPK catego-
ries were MAP4K1, MAP4K5, epidermal growth factor receptor
(EGFR) (ERBB1), AXIN1, GRM4, RAPGEF2 and TNIK. Second,
and using the same 350 input genes from the GWAS, Consensus-
PathDB identified ErbB4 signalling events as the category with the
most prominent overlap (six overlapping genes) with the input gene
list (P 5 8.8  104). This overlap included the genes ERBB4, EGFR
(ERBB1), FYN, GRIN2B, PTPRZ1 and WWOX (supplementary Table
3B is available at Carcinogenesis Online). Finally, and also with the
same 350 input genes, ToppGene ranked three genes related to MAPK
signalling pathways (EGFR, AXIN1 and PRKCA) among the four
best candidate genes from the GWAS (P , 2  105), whereas Top-
pNet tool selected five genes from the same categories (EGRF, FYN,
AXIN1, PRKCA and GRIN2B) among the 10 best candidates (P , 3 
104) (supplementary Tables 3C and D are available at Carcinogen-
esis Online). Combining the three approaches, a total of 15 genes
related to the overrepresented MAPK signalling pathways were de-
tected among the 350 genes from the 1340 most significantly associ-
ated SNPs from the GWAS.
Based on their biological function in the Entrez Gene database and
their direct implication in the MAPK signalling pathways for CRC
(45), only 7 of the 15 genes were selected as being directly involved in
MAPK signalling events. These genes were EGFR (ERBB1), ERBB4,
Table III. Association for the three SNPs in familial CRC cases of replications 1–3
Familial
cases
Controls ORhet. (95% CI) ORhom. (95% CI) Best model P value OR (95% CI)
rs12701937 (7p14.1) [T]
All replications 880 4790 1.35 (1.13–1.60) 1.39 (1.13–1.71) Dominant 2.0  104 1.36 (1.16–1.60)
GWAS þ replications 1251 6053 1.27 (1.09–1.46) 1.51 (1.27–1.80) Dominant 3.5  105 1.33 (1.16–1.52)
rs6038071 (20p13) [T]
All replications 861 3992 1.09 (0.90–1.32) 2.53 (1.37–4.67) Recessive 2.5  103 2.49 (1.35–4.59)
GWAS þ replications 1232 5225 1.21 (1.03–1.42) 2.73 (1.58–4.73) Recessive 3.0  104 2.64 (1.52–4.57)
rs11014993 (10p12.1) [C]
All replications 861 3992 1.36 (1.17–1.60) 1.06 (0.75–1.50) Dominant 2.7  104 1.32 (1.14–1.54)
GWAS þ replications 1232 5225 1.20 (1.05–1.37) 1.38 (1.04–1.82) Dominant 2.0  103 1.22 (1.08–1.39)
Minor allele for each SNP is indicated in square brackets; OR (95% CI) for heterozygous (ORhet.) and homozygous (ORhom.) genotypes are shown; P value and OR
(95% CI) for the best model. All results were adjusted for study centre.







P , 0.05 P , 0.01 P , 0.001
Number categories P value Number categories P value Number categories P value
104 153 46 16 0.740 5 0.607 1 0.445
103 1340 350 213 0 73 0.001 7 0.072
5  103 5130 1057 156 0.155 27 0.342 3 0.400
Number of GO categories reaching various levels of significance for overrepresentation (P , 0.05, P , 0.01 or P , 0.001) on the list of significant SNPs and
their corresponding genes, together with P values indicating whether this number is significantly greater than that expected by chance. Most significant categories
were obtained using the 1340 SNPs from the GWAS with allelic P value , 103, located within 350 different genes.
Fig. 1. Genome-wide association results from the initial GWAS analysis. The log10 of the allelic P values from 610 664 polymorphic SNPs comparing 371
familial CRC cases and 1263 controls of German origin are represented. The chromosomal distribution is shown (Manhattan plot). The horizontal line represents















MAP4K1, MAP4K5, PRKCA, AXIN1 and RAPGEF2. Combining gen-
otypes of the seven most significantly associated SNPs (one from each
gene) for the 371 cases and 1263 controls from the GWAS, we cal-
culated ORs corresponding to an increasing number of risk alleles.
The risk of CRC increased significantly, with a per allele OR of 1.34,
95% CI 1.11–1.61 (Ptrend 5 2.2  1016). For carriers of more than
four risk alleles, the risk of disease was increased 3-fold (OR 2.88,
95% CI 2.26–3.67), compared with carriers of less than or equal to
four risk alleles (Figure 2; supplementary Table 4 is available at
Carcinogenesis Online).
Pair-wise interactions using logistic regression did not yield evidence
for epistasis between any pair of risk alleles, with only borderline
evidences of interaction for rs6593210–rs7251456 (EGFR–MAP4K1,
P 5 0.095) and rs11157745–rs7251456 (MAP4K5–MAP4K1,
P 5 0.064). Using MDR, the pair rs6593210–rs7251456 (EGFR–
MAP4K1) showed nominal evidence of an interaction, with a cross-
validation consistency of 10/10, testing balanced accuracy of 55.5%
and permutation P value of 0.015 (based on 1000 permutations). How-
ever, visualization of the corresponding interaction dendrogram re-
vealed redundant interaction between any pair of SNPs, without
evidence of epistatic relationship.
Discussion
In our GWAS, 371 familial CRC cases and 1263 healthy controls were
successfully genotyped. After stringent quality control, a total of 523
polymorphic SNPs showed a P value for association ,104 for either
allelic, genotype, dominant or recessive model.
Application of several functional and positional criteria led to the
selection of 51 SNPs for replication in a cohort of 575 familial CRC
cases and 760 controls (replication 1). Six of them showed nominal
association (P , 5  102) with the same allele as in the GWAS.
Three SNPs were selected for further replications (replications 2–4).
Polymorphism rs12701937, located between the genes GLI3 and
INHBA remained associated in the combined cohort (P 5 1.1 
103, OR 1.14, 95% CI 1.05–1.23 for a dominant model). Both
rs12701937 and its neighbouring marker rs10441105 (D# 5 1.0,
r2 5 0.62 in the HapMap CEU population) are located in a 37 kb
LD block at chromosome 7 (41.588–41.625 Mb), 50 kb upstream
from INHBA and 180 kb downstream from GLI3, not in LD with
any of the genes. The role of the sonic hedgehog (Shh) signalling,
which includes GLI3 as a mediator, in CRC remains controversial.
Alterations in the signalling have been shown in several cancer types
(48), although they do not seem to be common in CRC (49). INHBA
has been proposed as a potential marker for gastric (50) and head and
neck squamous cell carcinomas (51).
Already published GWASs for CRC and a meta-analysis have so far
identified 10 risk loci, with ORs ranging between 1.10 and 1.26 (20).
For loci on chromosome regions 8q24.21 and 11q23, our GWAS
identified SNPs (rs10956369 and rs12296076, respectively) with
P values ,104, which were confirmed in replication 1. The CRC
susceptibility locus at 8q24.21 (rs6983267) (5,6), also associated with
prostate, breast, ovarian and other cancers (52), was represented
with several SNPs in our GWAS. Apart from rs10956369, the most
significantly associated SNP in the region (allelic P 5 4.2  105,
OR 1.41, 95% CI 1.20–1.66), the three polymorphisms reported in the
previous GWASs showed also association (rs10505477, P 5 5.9 
104; rs6983267, P 5 7  104 and rs7014346, P 5 2.5  104).
Recently, rs6983267 has been functionally identified as the plausible
causal variant in the region (53,54). Since all these markers belong to
the same LD block, our association with rs10956369 and its adjacent
SNPs reflects the same signal as rs6983267. At chromosome 11q23,
rs12296076 (allelic P 5 2.4  104, OR 1.42, 95% CI 1.18–1.71) is
located 5 kb upstream of rs3802842, the most significantly associated
SNP in the original GWAS (4). This SNP is not present in the Affy-
metrix 6.0 array used by us, but it belongs to the same LD block
(D# 5 0.95, r2 5 0.79 in the HapMap CEU population). Interest-
ingly, rs12296076 has been identified in silico as a polymorphic-
binding site for miRNAs (4). No mutations have been identified in
any of the transcripts in the region (16), thus the exact nature of the
association remains unknown.
In an attempt to enhance the case group with ‘genetically enriched’
cases (55), all 371 CRC patients in our GWAS had at least one first-
degree relative with CRC. This strategy of selecting only familial
cases increases the efficiency and power of the case–control associa-
tion study (23) and reduces the sample size required to detect common
disease susceptibility alleles (22). Association results for familial
cases, which were genotyped for three SNPs in replications 1–3, are
consistent with this theory because the association signal for familial
cases was stronger than for all patients, which were mostly sporadic.
These results might indicate that markers selected from the GWAS for
replication are more specific for familial than for sporadic CRC cases.
On the other hand, the limited number of patients investigated in the
GWAS (371 patients) compromised the power to detect weak signals
expected in a common disease like CRC. For example, the known risk
locus at 8q24.21 would not have passed our SNP selection criteria, if it
had not been implicated in the previous GWASs.
Only a small fraction of the estimated heritability for CRC (6% of
the full-sibling relative risk) can be explained by the so far discovered
10 low-risk loci (20). The missing heritability might be accounted by
many additional common genetic variants with even smaller effect
sizes (56), by rare variants with moderate to high penetrance which
are not gauged by the GWA platforms (21), by copy number variants
(57) or by more complex gene–gene (46) and gene–environment inter-
actions (58). There is an increasing interest in searching for networks of
genes, instead of single genes, contributing to disease (24). Accord-
ingly, we searched for enrichment of particular pathways or GO cate-
gories among the 1340 most significantly associated markers from the
GWAS (allelic P value , 103), located within 350 genes. Using this
input information, three different software tools pointed to the over-
representation of genes related to the MAPK signalling pathways. We
consider these results of special interest because enrichment tools are
being an object of discussion due to their heterogeneity in the type of
statistical analysis performed and lack of reproducibility of results
among tools (59). The direct involvement of the MAPK signalling
pathways in CRC is well known (45), and several recently developed
drugs for CRC treatment are antagonist of EGFR, activation of which is
the main trigger of the MAPK signalling cascade (60). Thus, these
results demonstrate the validity of the enrichment approaches used
and they provide a proof-of-principle demonstration (42). Using the
genotypes from the GWAS, we observed a significant increase in ORs
with the number of risk alleles from seven SNPs selected from the
Fig. 2. Sample distribution according to the number of risk alleles in seven
of the most significantly associated SNPs from the MAPK signalling
pathway genes. CRC cases (n 5 371, grey columns), controls (n 5 1263,
black columns).














overrepresented MAPK categories (Ptrend 5 2.2  1016,
ORper allele 5 1.34, 95% CI 1.11–1.61), with an OR 2.88 (95% CI
2.26–3.67) for carriers of more than four risk alleles. Pair-wise
combinations and MDR analysis provided no evidence of
interactive effects between any of the seven risk alleles from
MAPK-related genes, suggesting that each locus independently car-
ries CRC risk.
In conclusion, our GWAS replicated two known risk loci for CRC
at chromosomes 8q24.21 and 11q23 and identified a possible new risk
polymorphism, rs12701937, which should now be tested in larger
studies. The overrepresentation analysis successfully identified an
enrichment of the MAPK signalling pathways among the most sig-
nificantly associated markers, and accumulation of risk alleles in an
individual increased CRC risk. This and other similar approaches are
clearly needed in order to reveal the large proportion of missing
heritability of complex diseases such as CRC.
Supplementary material
Supplementary Tables 1–4 and Figure 1 can be found at http://carcin
.oxfordjournals.org/
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